Icrucumab, an novel monoclonal protein, is currently undergoing thorough clinical testing for its application in multiple inflammatory conditions. Early studies suggest a encouraging mechanism of action, selectively targeting the activity of IL-17, a crucial cytokine implicated in autoimmune reactions. The development path has encountered certai… Read More

Osocimab, formerly known as BAY 1213790, represents a unique monoclonal protein currently experiencing clinical evaluation for the treatment of several hematologic tumors. This compound primarily targets CD38, a cell receptor present on cancerous cells in conditions like multiple myeloma and acute myeloid leukemia. Preclinical data have indicate… Read More